In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Emtricitabine is a fluorinated derivative of lamivudine.
Atripla is emtricitabine, efavirenz and tenofovir disoproxil; Complera is emtricitabine, rilpivirine and tenofovir disoproxil; Descovy is emtricitabine and tenofovir alafenamide; Truvada is emtricitabine and tenofovir disoproxil.
See also separate profiles for emtricitabine in combination with cobicistat, elvitegravir and tenofovir disoproxil or tenofovir alafenamide.
LACTIC ACIDOSIS / SEVERE HEPATOMEGALY WITH STEATOSIS and POST TREATMENT EXACERBATION OF HEPATITIS B
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of emtricitabine with tenofovir disoproxil in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)